A phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of sipavibart in healthy Japanese adults.
BACKGROUND Sipavibart, a recombinant human immunoglobulin G1-based monoclonal antibody against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein, is approved in Japan for prevention of COVID-19 in immunocompromised individuals. This phase 1 study evaluated the safety and pharmacokinetics (PK) o...